Filing identity and reporting period
The supplied filing is Obalon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed June 19, 2020. This does not match the request metadata naming Vyome Holdings, Inc.; verify the issuer before relying on this summary.
Obalon was a medical-device company focused on its FDA-approved Obalon Balloon System for weight loss. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless stated otherwise.
Financial performance and position
| Metric | Q1 2020 | Q1 2019 / prior date |
|---|---|---|
| Revenue | $0.780 million | $1.775 million |
| Gross profit / margin | $0.239 million / 30.6% | $0.543 million / 30.6% |
| Research and development | $1.257 million | $2.439 million |
| Selling, general and administrative | $3.893 million | $6.204 million |
| Operating loss | $4.911 million | $8.100 million |
| Net loss | $5.261 million | $8.290 million |
| Net loss per share, basic and diluted | $0.68 | $3.59 |
| Cash and cash equivalents | $8.915 million | $14.055 million at Dec. 31, 2019 |
| Net cash used in operating activities | $4.814 million | $9.642 million |
Revenue fell about 56% year over year. Operating expenses declined, but the company remained loss-making. Cash declined by $5.140 million during the quarter. At March 31, current assets were $15.570 million and current liabilities were $7.188 million; total liabilities were $8.157 million. The balance sheet reported $1.659 million of lease liabilities. The company said it had repaid its prior debt in 2019 and reported no loan proceeds in Q1 2020.
Material changes and unusual items
- Revenue declined as U.S. sales and Middle East distributor sales decreased amid a changed commercial model. The company reported that Al Danah represented 30.8% of Q1 revenue and 52.1% of accounts receivable at March 31.
- Other expense of $0.385 million included fees for the Lincoln Park equity facility, which the company expensed after concluding use of the facility during the rest of 2020 was unlikely. No shares had been sold under the facility by March 31.
- Other current liabilities included a $3.150 million settlement accrual, with a corresponding $3.150 million insurance receivable in other current assets. In June, the parties reached a $3.15 million settlement of the securities class action, subject to court approval; the company expected insurance to cover amounts due.
- After quarter-end, the company received a $430,047 Paycheck Protection Program loan at 1% interest, due April 22, 2022, with payments deferred for six months. Forgiveness was not assured.
Outlook, risks, and contingencies
COVID-19 disruption led Obalon to suspend new patient treatments, close its retail centers, stop shipments and halt manufacturing. It terminated its international distributor agreement and said it did not expect meaningful revenue for the foreseeable future. After quarter-end, management shifted focus toward seeking third-party reimbursement and evaluating strategic alternatives; success was uncertain and could require additional capital.
The company stated that cash at March 31 was expected to fund operations through the end of 2020, but also disclosed substantial doubt about its ability to continue as a going concern for the twelve months following issuance of the financial statements. It warned that failure to raise capital or secure a strategic alternative could lead to asset sales, liquidation or bankruptcy. Management expected only two full-time employees after restructuring; approximately 25 employees were notified of termination in June, with about $0.2 million of expected cash charges.
Obalon expected a second-quarter 2020 impairment charge of $0.8 million to $1.4 million for inventory and long-lived assets. It had not recorded a COVID-related impairment in Q1. It also had unpaid rent obligations for its Carlsbad headquarters/manufacturing facility and Orange County retail center, and had received a landlord demand letter. Nasdaq listing compliance and a low share price were identified as risks. Disclosure controls were assessed as effective at the reasonable-assurance level as of March 31.
Most important facts for investors to verify
- Confirm that this Obalon filing, rather than a Vyome filing, is the intended document.
- Check subsequent cash balances, actual cash runway, financing availability and progress on strategic alternatives or reimbursement efforts.
- Verify court approval and insurance payment of the $3.15 million settlement, including whether the recorded receivable is collectible.
- Review the actual Q2 impairment charge and status of inventory, manufacturing and lease obligations.
- Confirm PPP loan eligibility, use of proceeds, repayment or forgiveness, and continuing Nasdaq listing compliance.